02/10/2019 - Press release
It is an initiative with no precedents, 20 relevant people of Catalonia and Balearic Island ask for tackling with urgency the crisis of plastic waste after checking the presence of plastic in its body derived from plasticized food in the entire distribution chain and consumption. Rezero collected 20 urine samples from 20 participants.Once samples were collected, samples were analyzed from Norwegian Institute of Public Health (www.fhi.no/en), referencelaboratory at international level on the detection of metabolic plastic in human samples. Specifically, it have been analyzed the presence of 27 components related to plastic exposition: 15 phthalates and 12 phenols. Results have been supervised by Doctor Miquel Porta, professor of Preventive Medicine and health and researcher at IMIM. He informed to all participants the results face to face and corroborated the faces of surprise and the impact of theparticipants.
08/10/2019 - Press release
Based on a study of 566 drugs that interact with 129 different proteins, researchers from the Systems Pharmacology research group, part of the GRIB Research Programme on Biomedical Informatics, a joint programme between the Hospital del Mar Medical Research Institute (IMIM) and Pompeu Fabra University (UPF), in collaboration with researchers from the University of New Mexico, in the United States, realised that 71% of drugs have stronger affinities for their target proteins than those of the small internal molecules responsible for regulating their functions. Surprisingly, this is the first time that the affinities of endogenous ligands and drugs for the same proteins have been quantified. Humans have thousands of proteins, each with a specific function that is often regulated by thousands of small molecules synthesised by our bodies. This set of small molecules, also known as "endogenous metabolites", is known as the "human metabolome". Each one interacts with its native protein with a certain affinity that has been carefully optimised, in a natural way, throughout the long process of evolution, and this can vary between species and even in some instances, more subtly, between individuals.
Més informació "Our own bodies hold the key to designing safer drugs"
23/08/2019 - Press release
Researchers from the Molecular Cancer group at the Hospital del Mar Medical Research Institute (IMIM) and doctors from Hospital del Mar, have demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment. The preliminary results of an ongoing clinical trial show that TAK-228, a mTORC1/2 protein inhibitor, can stop the progression of the disease. Four of the seven patients in the trial showed positive results. The trial also involved Hospital de la Santa Creu i Sant Pau in Barcelona, Hospital Universitari Parc Taulí in Sabadell, Clínica Universitaria in Navarre, and Hospital General Universitario in Elche.
Més informació "Effectiveness of a new bladder cancer treatment demonstrated"
10/07/2019 - Press release
A study led by researchers from the Hospital del Mar Medical Research Institute (IMIM), has determined, for the first time, the importance of a cell mechanism that may be key to treating metastatic tumours. The work has demonstrated the role a protein, kinase IKKα, plays in the ability of tumour cells to repair themselves. This is a key factor in treatment resistance and tumour spread. The research has been published in the journal Molecular Cell. The researchers analysed the role of this protein, activated by mutations of the BRAF and KRAS oncogenes, present in the majority of the most aggressive tumours. The function of this protein is to facilitate DNA-repair in tumour cells after they have been damaged by chemotherapy, making them more resistant to the action of these drugs. This is key for the treatment approach, since this new study demonstrates, conclusively, that combining a BRAF oncogene inhibitor with chemotherapy deactivates and kills the tumour.
Més informació "Mechanism determined for treating the most aggressive tumours"
28/06/2019 - Press release
The ageing of NK lymphocytes circulating in the blood of patients with HER2-positive breast cancer is a marker that can predict the success or failure of monoclonal antibody therapies, which act on a specific factor in tumour cells. This is the conclusion of a study led by researchers from the Hospital del Mar Medical Research Institute (IMIM) and the Pompeu Fabra University, and doctors from the Hospital del Mar, published in the journal Cancer Immunology Research. The study also involved staff from the Medical Oncology Service at Hospital Clínic in Valencia, the Pathological Anatomy Services at Hospital del Mar, Fundación Jiménez Díaz in Madrid, and the Immunogenetics Service at Puerta de Hierro University Institute, also in Madrid. It involved analysing blood samples from 66 patients, immunogenetic and functional studies of the NK lymphocytes of these patients, as well as analysing tumour biopsies. The ageing of these cells was measured by quantifying the NK lymphocytes in the blood that express the CD57 molecule. The results show that patients with high blood counts at the time of diagnosis are more likely to be resistant to chemotherapy and anti-HER2 antibody treatment.
Més informació "Possible marker of treatment resistance in HER2 breast cancer identified"
19/06/2019 - Press release
Researchers from the UAB and the IMIM published in Scientific Reports the first evidence in a non-human species, the domestic dog, of a relation between joint hypermobility and excitability: dogs with more joint mobility and flexibility tend to have more anxiety problems. The relation between collagen laxity and anxiety in humans is widely known, but this relation has never been observed before in other species. A team of researchers led by professors Jaume Fatjó and Antoni Bulbena from the Department of Psychiatry and Legal Medicine at the UAB, the Hospital del Mar Medical Research Institute (IMIM) and the UAB Affinity Foundation Chair in Animals and Health, analysed a set of 13 animal behaviour characteristics and hip joint mobility in a total of 5575 domestic dogs. The results point to an association between hip joint hypermobility and a brain activation linked to emotions in dogs, with similar results as to those observed in people.
Més informació "Joint Hypermobility Related to Anxiety, Also in Animals"
13/05/2019 - Events
BSC, UPC and IMIM organize the first Advances in Computational Biology conference will bring together researchers working on systems biology, omics technologies, artificial intelligence and high-performance computing (HPC) with applications to biology from both the public and the private sectors. The conference will be held November 28-29 in La Pedrera (Barcelona). Maria Jose Rementeria, Social Link Analytics group leader at the Barcelona Supercomputing Center (BSC) and one of the organizers, states: "One of the main purposes of the conference is to visualize and promote the research done by women scientists and for this reason all presenters will be women, although the conference is open to everyone. We want to create a space to foster collaborations between scientists, providing a unique opportunity to share ideas and build research networks".
Més informació "A conference to promote women's research in computational biology"
09/05/2019 - General information
The GRIB Integrative Biomedical Informatics group (IMIM-UPF) has launched a new version of DisGeNET, a public knowledge management platform on the genomics of disease, which is celebrating its tenth anniversary this year. DisGeNET offers information on genes and genomic variants associated with human diseases, which is obtained by integrating more than a dozen public resources and the scientific literature. DisGeNET contains one of the most comprehensive collections of genes and variants associated with human diseases that is currently available. The new version of DisGeNET (6.0) contains approximately 600,000 associations between more than 17,000 genes and 24,000 human diseases, focusing particularly on genetic alterations associated with disease: this version includes more than 117,000 genomic variants associated with 10,000 diseases. In addition, the phenotypic landscape covered by DisGeNET has been expanded to include the genomic basis of clinical manifestations of diseases, both signs and symptoms, as well as laboratory tests results.
Més informació "New version of DisGeNET 6.0 and ELIXIR recognition"
10/04/2019 - General information
The project EOSC-Life aims to create an open collaborative digital space for life science in the European Open Science Cloud (EOSC). EOSC-Life brings together the 13 european research infrastructures in the Health and Food domain of the ESFRI Roadmap and is funded by H2020 for the period 2019-2023. The project involves research groups from 46 European academic institutions. These include the GRIB Systems Pharmacology research group (IMIM-UPF) led by Jordi Mestres, which is helping develop collaborative tools for integrating and analysing all kinds of data in the field of life sciences.
05/04/2019 - Institutional news
Provisional relationship of advice and excluded aspirant persons that have been submitted to the external call for the merits competition, for the provision of a job of HUMAN RESOURCES DIRECTOR Mar Institute of Medical Research Foundation Managing body of the Hospital del Mar Medical Research Institute (IMIM) (Call FIMIM_01/2019).
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
